id,sentences,label,sentences_tokens,cuis
0,17 |||  ||| 0.17 ||| O grupo tratado com o misoprostol recebeu 25 μg cada 2 horas durante um máximo de 24 horas para indu??o.,N,grupo tratado misoprostol recebeu 25 cada 2 horas durante um mximo de 24 horas para induo,G0000000|G0000000|C0085174|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0011198|C0450371|G0000000|C0030563|G0000000
1,"62 ||| Study population ||| 3.8 ||| If the ideal pattern of uterine activites (at least 3 contractions per 10 minutes) was reached over 1 hour, misoprostol was no longer administered.",I,ideal pattern uterine activites 3 contractions 10 minutes reached 1 hour misoprostol administered,C1512612|C0449774|C0042149|G0000000|G0000000|C1140999|C0450371|C0439232|C2584321|G0000000|C0439227|C0085174|C1521801
2,"41 ||| Introduction ||| 1.15 ||| The exclusion criteria were lack of satisfaction for incorporation in the study, a positive history of uterine surgery including cesarean, intrauterine growth retardation (IUGR), oligohydramnios, placenta previa, umbilical cord prolapse, active herpes infection, symptoms of chorioamnionitis, hepatic or renal disease, non-reactive contraindications for prostaglandins use, contraindications for labor induction, and idiopathic vaginal bleeding.",P,exclusion criteria lack satisfaction incorporation study positive history uterine surgery including cesarean intrauterine growth retardation iugr oligohydramnios placenta previa umbilical cord prolapse active herpes infection symptoms chorioamnionitis hepatic renal disease non-reactive contraindications prostaglandins contraindications labor induction idiopathic vaginal bleeding,C0680251|C0243161|C0332268|C0242428|C0243126|C0557651|C0439178|C0019664|C0042149|C0038894|C0332257|C3841297|C0694756|C0018270|C0521111|C0015934|C0079924|C0032043|G0000000|C0041638|C1550235|C0033377|C0205177|C0019340|C0009450|C0683368|C0008495|C0205054|C0022646|C0012634|C1295728|C0079164|C0033554|C0079164|C0022864|C0205263|C0332240|C0042232|C0019080
3,82 ||| Baseline characteristics ||| 6.5 ||| Induction results,N,induction,C0205263
4,"42 ||| Introduction ||| 1.16 ||| As soon as the patients presented to delivery ward, baseline demographic and obstetric data including age, parity, body mass index (BMI), and past medical events were recorded and thereafter all the patients were evaluated for Bishop's score by a senior resident physician.",P,patients delivery ward baseline demographic obstetric data including age parity body mass bmi medical events recorded patients evaluated bishops score senior resident physician,C0030705|C0011209|C1305702|C0168634|C0011298|C0205484|C1511726|C0332257|C0001779|C0030563|C0242821|C0577559|G0000000|C0199168|C0441471|C0034869|C0030705|C0220825|C0649610|C0449820|C1705825|C1320928|C0031831
5,69 ||| Study population ||| 3.15 ||| Adequate uterine contractions were defined as at least 3 contractions per 10 minutes and lasting 60-90 seconds.,P,adequate uterine contractions defined 3 contractions 10 minutes lasting 60-90,C0205410|C0042149|C1140999|C1704788|G0000000|C1140999|C0450371|C0439232|C1517741|C0450371
6,"22 |||  ||| 0.22 ||| Apesar da falha mais prevalente no grupo tratado com oxitocina, os intervalos médios entre indu??o e fase ativa e trabalho de parto nesse grupo foram ambos significativamente menores em rela??o ao grupo tratado com misoprostol (10,1±6,1 e 13,2±7,7 versus 12,9±5,4 and 15,6±5,1 horas, respectivamente, sendo ambos os p-valores <0,05).",N,apesar da falha mais prevalente grupo tratado oxitocina os intervalos mdios entre induo fase ativa trabalho de parto nesse grupo foram ambos significativamente menores em relao ao grupo tratado misoprostol 10 16 1 13 27 7 versus 12 95 4 15 65 1 horas respectivamente sendo ambos os p-valores <0 05,G0000000|C0011318|G0000000|C0026914|G0000000|G0000000|G0000000|G0000000|C0229090|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0011198|G0000000|G0000000|G0000000|C0599385|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0085174|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|C0229090|C0369773|G0000000|C0450371
7,80 ||| Baseline characteristics ||| 6.3 ||| Demographic and clinical characteristics of patients are shown in the Table 1.,N,demographic clinical characteristics patients table 1,C0011298|C0205210|C1521970|C0030705|C0039224|G0000000
8,27 ||| Introduction ||| 1.1 ||| Labor induction is one of the most common procedures carried out worldwide for delivering mothers 1 .,N,labor induction common procedures carried worldwide delivering mothers 1,C0022864|C0205263|C0205214|C0025664|C0206243|G0000000|C0308779|C0026591|G0000000
9,112 ||| Discussion ||| 7.12 ||| 17,N,17,C0450371
10,14 |||  ||| 0.14 ||| OBJETIVO: Avaliar a eficácia e seguran?a do misoprostol administrado por via oral em compara??o à infus?o de oxitocina para a indu??o do trabalho de parto em gestantes a termo.,P,objetivo avaliar eficcia segurana misoprostol administrado por oral em comparao infuso de oxitocina para induo trabalho de parto em gestantes termo,G0000000|G0000000|G0000000|G0000000|C0085174|G0000000|C4048713|C0442027|G0000000|G0000000|G0000000|C0011198|G0000000|C0030563|G0000000|G0000000|C0011198|G0000000|G0000000|G0000000|G0000000
11,73 ||| Study population ||| 3.19 ||| All women were given standard postpartum care and discharged after 48 hours.,I,women standard postpartum care discharged 48 hours,C0043210|C1442989|C0086839|C1947933|C0030685|C0450371|C0439227
12,"32 ||| Introduction ||| 1.6 ||| Oxytocin and prostaglandins, such as misoprostol, are used for the induction of labor.",N,oxytocin prostaglandins misoprostol induction labor,C0030095|C0033554|C0085174|C0205263|C0022864
13,"26 |||  ||| 0.26 ||| Ensaio clínico registrado no Iranian Registry of Clinical Trials, number IRCT2012061910068N1.",N,ensaio clnico registrado iranian registry clinical trials irct2012061910068n1,G0000000|G0000000|G0000000|C1553355|C0034975|C0205210|C0008976|G0000000
14,"109 ||| Discussion ||| 7.9 ||| On the other hand, results of Fonseca's et al.",N,hand fonsecas al,C0018563|G0000000|C0202311
15,"6 |||  ||| 0.6 ||| The time from induction to delivery and induction to the beginning of the active phase and successful inductions within 12, 18, and 24 hours were recorded.",N,time induction delivery induction active phase successful inductions 12 18 24 hours recorded,C0040223|C0205263|C0011209|C0205263|C0205177|C0205390|C0597535|C0857127|C0450371|C0450371|C0450371|C0439227|C0034869
16,35 ||| Introduction ||| 1.9 ||| The usual method for inducing labor in our country is the use of oxytocin (Syntocinon) due to ethical-social concerns about the potential risk of abuse of misoprostol as an abortifacient drug.,N,usual method inducing labor country oxytocin syntocinon ethical-social concerns potential risk abuse misoprostol abortifacient drug,C3538928|C0025663|C0205263|C0022864|C0454664|C0030095|C0592155|C0026531|C2699424|C3245505|C0035647|C0013146|C0085174|C0000782|C0013227
17,5 |||  ||| 0.5 ||| The oxytocin group received an infusion of 10 IU which was gradually increased.,I,oxytocin received infusion 10 iu gradually increased,C0030095|C1514756|C0574032|C0450371|C0049272|G0000000|C0205217
18,125 ||| Discussion ||| 7.25 ||| Vaginal delivery is seen more frequently with misoprostol than oxytocin.,I,vaginal delivery frequently misoprostol oxytocin,C0042232|C0011209|C0332183|C0085174|C0030095
19,53 ||| Introduction ||| 1.27 ||| Sample size was determined after consideration of type1 statistical error <5%; and type2 statistical error <20%.,N,sample size determined consideration type1 statistical error <5% type2 statistical error <20%,C0370003|C0456389|G0000000|C0518609|G0000000|C0038215|C0743559|G0000000|G0000000|C0038215|C0743559|C0450371
20,12 |||  ||| 0.12 ||| Failure is seen less with misoprostol and caesarean sections are less frequently indicated as compared to oxytocin.,N,failure misoprostol caesarean sections frequently compared oxytocin,C0231174|C0085174|C3841297|C0152060|C0332183|C1707455|C0030095
21,"87 ||| Baseline characteristics ||| 6.10 ||| The primary parameters used to evaluate adverse events were the rate of cesarean section and its indication and serious maternal complications such as uterine hyperstimulation, uterine rupture, and placental abruption.",N,primary parameters evaluate adverse events rate cesarean indication maternal complications uterine hyperstimulation uterine rupture placental abruption,C0205225|C0449381|C0220825|G0000000|C0441471|C0871208|C3841297|C0392360|C2347083|C0009566|C0042149|G0000000|C0042149|C1881712|C0032043|G0000000
22,30 ||| Introduction ||| 1.4 ||| The benefits of labor induction must be weighed against the potential maternal and fetal risks associated with this procedure.,P,benefits labor induction weighed potential maternal fetal risks procedure,C0814225|C0022864|C0205263|G0000000|C3245505|C2347083|C0015965|C0035647|C0184661
23,"94 ||| Baseline characteristics ||| 6.17 ||| Except for the gastrointestinal symptoms, there were no statistically significant differences between the oxytocin and misoprostol patients groups in terms of other maternal complications (Table 3).",O,gastrointestinal symptoms statistically differences oxytocin misoprostol patients terms maternal complications table 3,C0521362|C0683368|C0038215|C1705241|C0030095|C0085174|C0030705|C0233324|C2347083|C0009566|C0039224|G0000000
24,"116 ||| Discussion ||| 7.16 ||| A shorter interval for oxytocin in comparison with misoprostol was also reported in another study (8.4±4.1 hours versus 11.3 ±6.9 hours, p<0.05) 17",I,shorter interval oxytocin comparison misoprostol reported study 8 44 1 hours versus 11 3 6 9 hours p<0 05 17,C1282927|C1272706|C0030095|C1707455|C0085174|C0684224|C0557651|G0000000|C0450371|G0000000|C0439227|G0000000|C0450371|G0000000|G0000000|G0000000|C0439227|C0369773|C0450371|C0450371
25,110 ||| Discussion ||| 7.10 ||| In another study 120 patients were enrolled in misoprostol (57 cases) and oxytocin (63 cases) groups.,P,study 120 patients enrolled misoprostol 57 oxytocin 63,C0557651|C1442061|C0030705|G0000000|C0085174|C0450371|C0030095|C0450371
26,"3 |||  ||| 0.3 ||| Twenty five patients were excluded for different reasons; and 260 included women were randomly assigned to one of the two groups according to the method of treatment, misoprostol or oxytocin.",P,twenty patients excluded reasons 260 included women randomly assigned method treatment misoprostol oxytocin,C0724000|C0030705|C1554077|C0392360|C1442061|C0332257|C0043210|G0000000|C1516050|C0025663|C0039798|C0085174|C0030095
27,"10 |||  ||| 0.10 ||| Maternal and fetal complications were comparable between groups except gastrointestinal symptoms which were encountered more frequently in the misoprostol (10.9 versus 3.9%, p=0.03).",O,maternal fetal complications comparable gastrointestinal symptoms encountered frequently misoprostol 10 9 versus 3 9% p=0 03,C2347083|C0015965|C0009566|G0000000|C0521362|C0683368|C0545082|C0332183|C0085174|C0450371|G0000000|G0000000|G0000000|G0000000|C0369773|C0450371
28,52 ||| Introduction ||| 1.26 ||| It was not possible to blind the study participants and personnel from knowledge of which intervention a participant received because both methods were clearly different.,I,blind study participants personnel knowledge intervention participant received methods,C0150108|C0557651|C0679646|C0024752|C0376554|C0886296|C0679646|C1514756|C0025663
29,56 ||| Study population ||| 3.2 ||| All patients provided an informed written consent; the study was approved by ethical committee of Shahid Beheshti University of Medical Sciences.,N,patients provided informed written consent study approved ethical committee shahid beheshti university medical sciences,C0030705|C1999230|C1522154|C0043266|C1511481|C0557651|C0205540|C0026531|C2699414|G0000000|G0000000|C0041740|C0199168|C0036397
30,"81 ||| Baseline characteristics ||| 6.4 ||| There was no significant difference between the groups regarding any of the studied parameters including age, nulliparity, gestational age, BMI, Bishop's score, premature rupture of membranes, and indication for labor induction.",P,difference studied parameters including age nulliparity gestational age bmi bishops score premature rupture membranes indication labor induction,C1705241|C0557651|C0449381|C0332257|C0001779|C0028641|C0439671|C0001779|G0000000|C0649610|C0449820|C0151526|C1881712|C0025255|C0392360|C0022864|C0205263
31,"63 ||| Study population ||| 3.9 ||| The practical strategies common to the administration of intravenous oxytocin or oral misoprostol solution were as follows: monitoring of FHR and intrapartum uterine activity was performed continuously; in the presence of any tachysystole or hypertonus, or changes in FHR associated with tachysystole or hypertonus, infusion rate was decreased or stopped; intravenous magnesium sulfate (4 g over 30 minutes) could be given at the discretion of the physician if uterine hyperstimulation occurred.",I,practical strategies common administration intravenous oxytocin oral misoprostol solution monitoring fhr intrapartum uterine activity performed continuously presence tachysystole hypertonus fhr tachysystole hypertonus infusion rate decreased stopped intravenous magnesium sulfate 4 30 minutes discretion physician uterine hyperstimulation occurred,G0000000|C0679199|C0205214|C0001554|C0348016|C0030095|C0442027|C0085174|C0037633|C0150369|G0000000|C0456337|C0042149|C0205177|C0884358|G0000000|C0150312|C2985339|C0026826|G0000000|C2985339|C0026826|C0574032|C0871208|C0205216|C1272691|C0348016|C0024467|C0038720|G0000000|C0450371|C0439232|G0000000|C0031831|C0042149|G0000000|C1709305
32,"47 ||| Introduction ||| 1.21 ||| Despite numerous reports on this issue, the question remains on efficacy and maternal/neonatal safety of oxytocin and misoprostol.",O,numerous reports issue question remains efficacy maternal/neonatal safety oxytocin misoprostol,C0439064|C0684224|C0033213|C1522634|G0000000|C1280519|C2347083|C0036043|C0030095|C0085174
33,"20 |||  ||| 0.20 ||| O ensaio foi registrado em irct.ir, número IRCT2012061910068N1.",N,ensaio foi registrado em irct ir nmero irct2012061910068n1,G0000000|C0086325|G0000000|G0000000|G0000000|C0022065|G0000000|G0000000
34,114 ||| Discussion ||| 7.14 ||| Fonseca et al.,N,fonseca al,G0000000|C0202311
35,"75 ||| Statistical analysis ||| 4.2 ||| Statistical analysis was performed using the SPSS 16.0 statistical software package (SPSS Inc, Chicago, IL, USA).",N,statistical analysis performed spss 16 0 statistical software package spss chicago il usa,C0038215|C0002778|C0884358|C3813609|C0450371|G0000000|C0038215|C0037585|C0013194|C3813609|C0008044|C0020898|C0041703
36,"60 ||| Study population ||| 3.6 ||| If contractions did not occur after 24 hours (twelve doses), no further misoprostol was given .",I,contractions occur 24 hours twelve doses misoprostol,C1140999|C1709305|C0450371|C0439227|C0205458|C0178602|C0085174
37,"31 ||| Introduction ||| 1.5 ||| When the benefits of expeditious delivery are greater than the risks of continuing the pregnancy, inducing labor can be justified as a therapeutic intervention 4 .",P,benefits expeditious delivery risks continuing pregnancy inducing labor justified therapeutic intervention 4,C0814225|C0015315|C0011209|C0035647|C0549178|C0032961|C0205263|C0022864|C1552821|C0087111|C0886296|G0000000
38,1 |||  ||| 0.1 ||| Indu??o do trabalho de parto por meio de solu??o oral titulada de misoprostol versus oxitocina em gesta??o a termo: estudo controlado randomizado Artigo Original Abstract PURPOSE: To evaluate the effectiveness and the safety of orally administered misoprostol in comparison to intravenously infused oxytocin for labor induction in term pregnant women.,P,induo trabalho de parto por meio de soluo oral titulada de misoprostol versus oxitocina em gestao termo estudo controlado randomizado artigo original abstract purpose evaluate effectiveness safety orally administered misoprostol comparison intravenously infused oxytocin labor induction term pregnant women,G0000000|G0000000|C0011198|G0000000|C4048713|G0000000|C0011198|G0000000|C0442027|G0000000|C0011198|C0085174|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0205313|C0000857|C1285529|C0220825|C1280519|C0036043|C0442027|C1521801|C0085174|C1707455|G0000000|G0000000|C0030095|C0022864|C0205263|C0233324|C0549206|C0043210
39,"8 |||  ||| 0.8 ||| RESULTS: Failure of induction, leading to caesarean section was around 38.3% in the oxytocin group and significantly higher than that of the misoprostol group (20.3%) (p<0.001).",O,failure induction leading caesarean 38 3% oxytocin misoprostol 20 3% p<0 001,C0231174|C0205263|C0332152|C3841297|C0450371|G0000000|C0030095|C0085174|C0450371|G0000000|C0369773|C1442061
40,"121 ||| Discussion ||| 7.21 ||| However, .",N,NULL,NULL
41,90 ||| Baseline characteristics ||| 6.13 ||| The most common indication for cesarean was lack of response to induction in both groups.,O,common indication cesarean lack response induction,C0205214|C0392360|C3841297|C0332268|C0871261|C0205263
42,"106 ||| Discussion ||| 7.6 ||| The cesarean section rate, latent period and period from induction to vaginal delivery were significantly lower for the misoprostol group other investigation is in favor of one method of induction.",O,cesarean rate latent period period induction vaginal delivery lower misoprostol investigation favor method induction,C3841297|C0871208|C0205275|C0439531|C0439531|C0205263|C0042232|C0011209|C0441994|C0085174|C0220825|C0309049|C0025663|C0205263
43,66 ||| Study population ||| 3.12 ||| Failure to progress was defined as the cervical dilation or fetal descent without any progress for 3 hours after entering the active labor phase as augmented by the agent.,P,failure progress defined cervical dilation fetal descent progress 3 hours entering active labor phase augmented agent,C0231174|C1272688|C1704788|C0027530|C0012359|C0015965|C0205386|C1272688|G0000000|C0439227|C1522196|C0205177|C0022864|C0205390|C0205217|C0450442
44,99 ||| Baseline characteristics ||| 6.22 ||| Only one patient (0.7%) in oxytocin group and none of the subjects in misoprostol group had meconium in amniotic fluid (p=1.0).,N,patient 0 7% oxytocin subjects misoprostol meconium amniotic fluid p=1 0,C0030705|G0000000|G0000000|C0030095|C0681850|C0085174|C0025047|C0002630|C0005889|C0369773|G0000000
45,"102 ||| Discussion ||| 7.2 ||| Many studies have stated the safety and feasibility, efficacy, stability, and low cost of the misoprostol for induction of labor at term with an unfavorable cervix Optimal dosing of misoprostol that will achieve effective induction without above mentioned side effects has been focused by many studies.",O,studies stated safety feasibility efficacy stability low cost misoprostol induction labor term unfavorable cervix optimal dosing misoprostol achieve effective induction mentioned effects focused studies,C0947630|C1301808|C0036043|G0000000|C1280519|C0205360|C0205251|C0010186|C0085174|C0205263|C0022864|C0233324|C3640815|C0007874|C2698651|G0000000|C0085174|G0000000|C1280519|C0205263|G0000000|C1280500|C0205234|C0947630
46,"18 |||  ||| 0.18 ||| O grupo tratado com oxitocina recebeu infus?o de 10 UI, que foi aumentada gradativamente.",N,grupo tratado oxitocina recebeu infuso de 10 ui foi aumentada gradativamente,G0000000|G0000000|G0000000|G0000000|G0000000|C0011198|C0450371|C1421312|C0086325|G0000000|G0000000
47,100 ||| Baseline characteristics ||| 6.23 ||| No maternal and neonatal deaths occurred in either group.,O,maternal neonatal deaths occurred,C2347083|C1552240|C0011065|C1709305
48,"37 ||| Introduction ||| 1.11 ||| However, dosage of misoprostol, administration interval, administration route was different in published series withdraw from the study at any time without being denied the standard clinical care.",N,dosage misoprostol administration interval administration route published series withdraw study time denied standard clinical care,C0178602|C0085174|C0001554|C1272706|C0001554|C0013153|C0034037|C0205549|C2349954|C0557651|C0040223|C0332319|C1442989|C0205210|C1947933
49,70 ||| Study population ||| 3.16 ||| Tachysystole was defined as the presence of at least five contractions in a 10-minutes interval.,N,tachysystole defined presence contractions 10-minutes interval,C2985339|C1704788|C0150312|C1140999|C0450371|C1272706
50,"19 |||  ||| 0.19 ||| O tempo a partir da indu??o até o início da fase ativa e as indu??es bem-sucedidas dentro de 12, 18 e 24 horas foram registrados.",O,tempo partir da induo incio da fase ativa indues bem-sucedidas dentro de 12 18 24 horas foram registrados,C0876945|G0000000|C0011318|G0000000|G0000000|C0011318|G0000000|G0000000|G0000000|C0280106|G0000000|C0011198|C0450371|C0450371|C0450371|G0000000|C0599385|G0000000
51,61 ||| Study population ||| 3.7 ||| The maximum dose 10 was 300 μg.,I,maximum dose 10 300,C0806909|C0178602|C0450371|C1442061
52,91 ||| Baseline characteristics ||| 6.14 ||| Labor characteristics and delivery outcome data are summarized in Table 2.,N,labor characteristics delivery outcome data summarized table 2,C0022864|C1521970|C0011209|C1274040|C1511726|G0000000|C0039224|G0000000
53,39 ||| Introduction ||| 1.13 ||| The inclusion criteria were women aged 18 years or older with a gestational age of 38 to 42 weeks and a singleton pregnancy who had request for elective termination of pregnancy before 42 weeks of gestation or had medical indication for labor induction (hypertension and diabetes).,P,inclusion criteria women aged 18 gestational age 38 42 weeks singleton pregnancy request elective termination pregnancy 42 weeks gestation medical indication labor induction hypertension diabetes,C0007637|C0243161|C0043210|C0001779|C0450371|C0439671|C0001779|C0450371|C0450371|C0439230|C0481462|C0032961|C1272683|C0206058|C1549081|C0032961|C0450371|C0439230|C0032961|C0199168|C0392360|C0022864|C0205263|C0020538|C0011847
54,"16 |||  ||| 0.16 ||| Vinte e cinco pacientes foram excluídas por várias raz?es, e as 260 mulheres incluídas foram divididas aleatoriamente em dois grupos de acordo com o método de tratamento, misoprostol ou oxitocina.",N,vinte cinco pacientes foram excludas por vrias razes 260 mulheres includas foram divididas aleatoriamente em dois grupos de acordo mtodo de tratamento misoprostol ou oxitocina,G0000000|G0000000|G0000000|C0599385|G0000000|C4048713|G0000000|G0000000|C1442061|G0000000|G0000000|C0599385|G0000000|G0000000|G0000000|C2348291|G0000000|C0011198|G0000000|G0000000|C0011198|G0000000|C0085174|C0229118|G0000000
55,"124 ||| Discussion ||| 7.24 ||| According to the results obtained in this clinical trial, the orally administered misoprostol could be mentioned as safe and effective as to intravenously infused oxytocin for labor induction in term pregnant women.",O,clinical trial orally administered misoprostol mentioned safe effective intravenously infused oxytocin labor induction term pregnant women,C0205210|C0008976|C0442027|C1521801|C0085174|G0000000|G0000000|C1280519|G0000000|G0000000|C0030095|C0022864|C0205263|C0233324|C0549206|C0043210
56,76 ||| Statistical analysis ||| 4.3 ||| Time intervals were analyzed with Mann-Whitney U test and other data were analyzed with the χ 2 for qualitative and Student's t-test for quantitative variables.,N,time intervals analyzed mann-whitney test data analyzed 2 qualitative students t-test quantitative variables,C0040223|C1272706|C0936012|G0000000|C0022885|C1511726|C0936012|G0000000|C0205556|C0038492|C0871472|C0392762|C0439828
57,"9 |||  ||| 0.9 ||| Despite the more prevalent failure in the oxytocin group, the mean time intervals from induction to active phase and labor of this group were both significantly less than the misoprostol group (10.1±6.1 and 13.2±7.7 versus 12.9±5.4 and 15.6±5.1 hours respectively, both p-values were <0.05).",I,prevalent failure oxytocin time intervals induction active phase labor misoprostol 10 16 1 13 27 7 versus 12 95 4 15 65 1 hours p-values <0 05,C0033105|C0231174|C0030095|C0040223|C1272706|C0205263|C0205177|C0205390|C0022864|C0085174|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|C0439227|C1709380|G0000000|C0450371
58,97 ||| Baseline characteristics ||| 6.20 ||| Fourteen patients (10.9%) in misoprostol group and 16 subjects (12.5%) in oxytocin group had fetal tachycardia (p=0.07).,P,fourteen patients 10 9% misoprostol 16 subjects 12 5% oxytocin fetal tachycardia p=0 07,C3715152|C0030705|C0450371|G0000000|C0085174|C0450371|C0681850|C0450371|G0000000|C0030095|C0015965|C0039231|C0369773|C0450371
59,"21 |||  ||| 0.21 ||| RESULTADOS: A falha de indu??o levando à necessidade de cesariana foi de aproximadamente 38.3% no grupo tratado com oxitocina, sendo significativamente maior em rela??o ao grupo tratado com misoprostol (20,3%) (p<0,001).",I,resultados falha de induo levando necessidade de cesariana foi de aproximadamente 38 3% grupo tratado oxitocina sendo significativamente maior em relao ao grupo tratado misoprostol 20 3% p<0 001,G0000000|G0000000|C0011198|G0000000|G0000000|G0000000|C0011198|G0000000|C0086325|C0011198|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0085174|C0450371|G0000000|C0369773|C1442061
60,"65 ||| Study population ||| 3.11 ||| Contractions with regular intervals which resulted in progressive cervical dilatation, effacement were considered effective in induction of labor.",N,contractions regular intervals progressive cervical dilatation effacement considered effective induction labor,C1140999|C0205272|C1272706|C0205329|C0027530|C0012359|C0552443|C0750591|C1280519|C0205263|C0022864
61,50 ||| Introduction ||| 1.24 ||| Patients were randomly assigned to one of two groups according to the method of treatment: oxytocin or misoprostol.,I,patients randomly assigned method treatment oxytocin misoprostol,C0030705|G0000000|C1516050|C0025663|C0039798|C0030095|C0085174
62,51 ||| Introduction ||| 1.25 ||| Randomization was carried out using computer-generated simple random tables in a 1:1 ratio.,I,randomization carried computer-generated simple random tables 1 1 ratio,C0034656|C0206243|C0009622|C0205352|C0034656|C0039224|G0000000|G0000000|C0456603
63,"98 ||| Baseline characteristics ||| 6.21 ||| Admission in neonatal intensive care unit was seen more frequently in oxytocin group (3.9%) than in misoprostol group (0.7%); however, this difference was not statistically significant (p=0.02).",O,admission neonatal intensive care unit frequently oxytocin 3 9% misoprostol 0 7% difference statistically p=0 02,C0184666|C1552240|C0162425|C1947933|C0439148|C0332183|C0030095|G0000000|G0000000|C0085174|G0000000|G0000000|C1705241|C0038215|C0369773|C0450371
64,57 ||| Study population ||| 3.3 ||| Women were assured that they had the right to refuse to participate and/or Initiation of labor induction was the time at which the first misoprostol dose was administered or the oxytocin infusion was started.,I,women assured refuse participate and/or initiation labor induction time misoprostol dose administered oxytocin infusion started,C0043210|G0000000|C0017095|G0000000|G0000000|C0589507|C0022864|C0205263|C0040223|C0085174|C0178602|C1521801|C0030095|C0574032|C1272689
65,93 ||| Baseline characteristics ||| 6.16 ||| Maternal complications,N,maternal complications,C2347083|C0009566
66,"119 ||| Discussion ||| 7.19 ||| The average time interval of drug prescription to vaginal delivery is related to the dose, route and administration interval of misoprostol or oxytocin in concurrence with favorable cervices for induction or previous administration of dinoprostone in pregnant women 14 .",O,average time interval drug prescription vaginal delivery dose route administration interval misoprostol oxytocin concurrence favorable cervices induction previous administration dinoprostone pregnant women 14,C1510992|C0040223|C1272706|C0013227|C0033080|C0042232|C0011209|C0178602|C0013153|C0001554|C1272706|C0085174|C0030095|C0205420|C3640814|C0007874|C0205263|C0205156|C0001554|C0012472|C0549206|C0043210|C0450371
67,101 ||| Discussion ||| 7.1 ||| Oxytocin and misoprostol are the most common drugs used for the induction of labor 2 .,O,oxytocin misoprostol common drugs induction labor 2,C0030095|C0085174|C0205214|C0013227|C0205263|C0022864|G0000000
68,38 ||| Introduction ||| 1.12 ||| Twenty-five patients were excluded for different reasons; 260 were included in the study.,P,twenty-five patients excluded reasons 260 included study,C3715062|C0030705|C1554077|C0392360|C1442061|C0332257|C0557651
69,64 ||| Study population ||| 3.10 ||| The active phase was defined as achieving adequate uterine contractions with cervical dilatation greater than 3 cm.,O,active phase defined achieving adequate uterine contractions cervical dilatation 3 cm,C0205177|C0205390|C1704788|G0000000|C0205410|C0042149|C1140999|C0027530|C0012359|G0000000|G0000000
70,71 ||| Study population ||| 3.17 ||| Hyperstimulation was defined as tachysystole or hypertonus with nonreassuring FHR changes.,N,hyperstimulation defined tachysystole hypertonus nonreassuring fhr,G0000000|C1704788|C2985339|C0026826|G0000000|G0000000
71,77 ||| Statistical analysis ||| 4.4 ||| A p-value of 0.05 was considered significant.,N,p-value 0 05 considered,C1709380|G0000000|C0450371|C0750591
72,92 ||| Baseline characteristics ||| 6.15 ||| Neonatal outcomes,N,neonatal outcomes,C1552240|C1274040
73,123 ||| Discussion ||| 7.23 ||| Inability to design a double blind clinical trial due to the different rout of drug administration was a major limitation of our study.,I,inability design double blind clinical trial rout drug administration major limitation study,G0000000|C1707689|C0205173|C0150108|C0205210|C0008976|G0000000|C0013227|C0001554|C0205082|C0449295|C0557651
74,"58 ||| Study population ||| 3.4 ||| In the oxytocin group, infusion rate of 2 mIU/min was prescribed for induction and gradually increased by 2 mIU/min every 15 minutes to a maximum dose of 36 mIU/min until adequate uterine contractions were attained.",I,oxytocin infusion rate 2 miu/min prescribed induction gradually increased 2 miu/min 15 minutes maximum dose 36 miu/min adequate uterine contractions attained,C0030095|C0574032|C0871208|G0000000|C0439455|C0278329|C0205263|G0000000|C0205217|G0000000|C0439455|C0450371|C0439232|C0806909|C0178602|C0450371|C0439455|C0205410|C0042149|C1140999|G0000000
75,29 ||| Introduction ||| 1.3 ||| Uterine contractions and an appropriate cervical ripening cervix are two important factors in labor contributing to good pregnancy outcomes 3 .,N,uterine contractions cervical ripening cervix factors labor contributing pregnancy outcomes 3,C0042149|C1140999|C0027530|C1160534|C0007874|C1521761|C0022864|C1880177|C0032961|C1274040|G0000000
76,117 ||| Discussion ||| 7.17 ||| 18,N,18,C0450371
77,"40 ||| Introduction ||| 1.14 ||| Additional criteria for enrollment were birth weight of maximally 4.000 gram, normal fetal heart rate, cephalic presentation, lack of uterine contractures, and Bishop's score of 6 or less.",P,additional criteria enrollment birth weight maximally 4 000 gram normal fetal heart rate cephalic presentation lack uterine contractures bishops score 6,C1524062|C0243161|C1516879|C0005615|C0005910|G0000000|G0000000|C1442061|C0439208|C0205307|C0015965|C0018787|C0871208|C0205096|C0449450|C0332268|C0042149|C0009917|C0649610|C0449820|G0000000
78,68 ||| Study population ||| 3.14 ||| Cesarean section was performed if hyperstimulation syndrome or fetal hypoxia (thick meconium and/or fetal monitoring alteration) were present and if induction was failed.,I,cesarean performed hyperstimulation syndrome fetal hypoxia thick meconium and/or fetal monitoring alteration induction failed,C3841297|C0884358|G0000000|C0039082|C0015965|C0242184|C1280412|C0025047|G0000000|C0015965|C0150369|C1515926|C0205263|C0231175
79,107 ||| Discussion ||| 7.7 ||| In a recent research among 240 pregnant women it was revealed that mean induction-to-vaginal delivery time with misoprostol was shorter than Foley catheter and oxytocin (17.3 versus 20.2 hours) 19 .,I,240 pregnant women revealed induction-to-vaginal delivery time misoprostol shorter foley catheter oxytocin 17 3 versus 20 2 hours 19,C1442061|C0549206|C0043210|C0443289|C0205263|C0011209|C0040223|C0085174|C1282927|G0000000|C0085590|C0030095|C0450371|G0000000|G0000000|C0450371|G0000000|C0439227|C0450371
80,"104 ||| Discussion ||| 7.4 ||| In our study, a dose of 25 μg which was repeated every 2 hours for up to 24 hours, was orally administered   groups in percentage of vaginal deliveries within the first 12 hours.",I,study dose 25 repeated 2 hours 24 hours orally administered percentage vaginal deliveries 12 hours,C0557651|C0178602|C0450371|C0205341|G0000000|C0439227|C0450371|C0439227|C0442027|C1521801|C0439165|C0042232|C0011209|C0450371|C0439227
81,11 |||  ||| 0.11 ||| CONCLUSIONS: Misoprostol is a safe and effective drug with low complications for the induction of labor.,O,conclusions misoprostol safe effective drug low complications induction labor,C1707478|C0085174|G0000000|C1280519|C0013227|C0205251|C0009566|C0205263|C0022864
82,79 ||| Baseline characteristics ||| 6.2 ||| Two hundred and fifty-six patients were able to complete the study and their data were included in the final analyses.,N,fifty-six patients complete study data included final analyses,C3816723|C0030705|C0205197|C0557651|C1511726|C0332257|C0205088|C0002778
83,111 ||| Discussion ||| 7.11 ||| Vaginal delivery occurred in 78.9 and 58.7% of misoprostol and oxytocin group respectively (p<0.05) study support the finding that the induction-to-delivery interval with oxytocin is shorter compared with misoprostol (13.1 versus 16.3 hours) 13,O,vaginal delivery occurred 78 9 58 7% misoprostol oxytocin p<0 05 study support finding induction-to-delivery interval oxytocin shorter compared misoprostol 13 1 versus 16 3 hours 13,C0042232|C0011209|C1709305|C0450371|G0000000|C0450371|G0000000|C0085174|C0030095|C0369773|C0450371|C0557651|C0183683|C0037088|C0205263|C1272706|C0030095|C1282927|C1707455|C0085174|C0450371|G0000000|G0000000|C0450371|G0000000|C0439227|C0450371
84,"15 |||  ||| 0.15 ||| MéTODOS: Entre 2008 e 2010, um total de 285 gestantes a termo candidatas para parto vaginal foram avaliadas quanto à eligibilidade para inclus?o no estudo.",P,mtodos entre 2008 2010 um total de 285 gestantes termo candidatas para parto vaginal foram avaliadas quanto eligibilidade para incluso estudo,G0000000|G0000000|G0000000|G0000000|G0000000|C0439175|C0011198|C1442061|G0000000|G0000000|G0000000|C0030563|G0000000|C0042232|C0599385|G0000000|C0309988|G0000000|C0030563|G0000000|G0000000
85,127 ||| Discussion ||| 7.27 ||| Maternal complications: comparison of labor induction with misoprostol or oxytocin,O,maternal complications comparison labor induction misoprostol oxytocin,C2347083|C0009566|C1707455|C0022864|C0205263|C0085174|C0030095
86,"115 ||| Discussion ||| 7.15 ||| Also, the total percentage of cesarean deliveries was not significantly different among these methods in Kramer's study .",N,total percentage cesarean deliveries methods kramers study,C0439175|C0439165|C3841297|C0011209|C0025663|C0331847|C0557651
87,4 |||  ||| 0.4 ||| The misoprostol group received 25 μg every 2 hours for up to 24 hours for induction.,I,misoprostol received 25 2 hours 24 hours induction,C0085174|C1514756|C0450371|G0000000|C0439227|C0450371|C0439227|C0205263
88,78 ||| Baseline characteristics ||| 6.1 ||| Two hundred and sixty consenting patients who fulfilled the entry criteria were enrolled in this study.,P,sixty consenting patients fulfilled entry criteria enrolled study,C3816724|C1511481|C0030705|C1550543|C1705654|C0243161|G0000000|C0557651
89,"84 ||| Baseline characteristics ||| 6.7 ||| Both values of mean time from induction to active phase and induction to delivery were significantly shorter in oxytocin group than in misoprostol group (10.1±6.1 and 13.2±7.7 versus 12.9±5.4 and 15.6±5.1 hours respectively, both p-values were <0.05).",I,values time induction active phase induction delivery shorter oxytocin misoprostol 10 16 1 13 27 7 versus 12 95 4 15 65 1 hours p-values <0 05,C0042295|C0040223|C0205263|C0205177|C0205390|C0205263|C0011209|C1282927|C0030095|C0085174|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000|C0439227|C1709380|G0000000|C0450371
90,"59 ||| Study population ||| 3.5 ||| In the misoprostol group, a tablet of 200 μg was dissolved in 200 cc of water and 25 cc was administered every 2 hours until adequate uterine contractions were achieved.",I,misoprostol tablet 200 dissolved 200 cc water 25 cc administered 2 hours adequate uterine contractions achieved,C0085174|C0039225|C1442061|C1549535|C1442061|C3538933|C0043047|C0450371|C3538933|C1521801|G0000000|C0439227|C0205410|C0042149|C1140999|G0000000
91,120 ||| Discussion ||| 7.20 ||| Most of these studies did not demonstrate a difference in the interval from treatment to delivery between groups of misoprostol and oxytocin.,O,studies demonstrate difference interval treatment delivery misoprostol oxytocin,C0947630|G0000000|C1705241|C1272706|C0039798|C0011209|C0085174|C0030095
92,"49 ||| Introduction ||| 1.23 ||| This was a single center balanced randomized parallelgroup study carried out in the Gynecology Department of Tajrish Hospital in Tehran, Iran.",P,single center balanced randomized parallelgroup study carried gynecology department tajrish hospital tehran iran,C0037179|C0205099|C0205415|C0034656|G0000000|C0557651|C0206243|C0018417|C1704729|G0000000|C0019994|G0000000|C0022065
93,"72 ||| Study population ||| 3.18 ||| FHR changes considered to be nonreassuring were late deceleration, severe variable deceleration, prolonged deceleration, tachycardia, or reduced FHR variability requiring intervention with either tocolytic or delivery.",O,fhr considered nonreassuring late deceleration severe variable deceleration prolonged deceleration tachycardia reduced fhr variability requiring intervention tocolytic delivery,G0000000|C0750591|G0000000|C0205087|C0011100|C0205082|C0439828|C0011100|C0439590|C0011100|C0039231|C0392756|G0000000|C2827666|G0000000|C0886296|C0040349|C0011209
94,"95 ||| Baseline characteristics ||| 6.18 ||| In fact, gastrointestinal symptoms were observed more frequently in the misoprostol than in the oxytocin group (10.9 versus 3.9%, p=0.03); all of them were treated conservatively.",N,gastrointestinal symptoms observed frequently misoprostol oxytocin 10 9 versus 3 9% p=0 03 treated conservatively,C0521362|C0683368|C1441672|C0332183|C0085174|C0030095|C0450371|G0000000|G0000000|G0000000|G0000000|C0369773|C0450371|C1522326|G0000000
95,"24 |||  ||| 0.24 ||| CONCLUS?ES: O misoprostol é droga segura e eficaz para a indu??o do parto, com poucas complica??es.",P,concluses misoprostol droga segura eficaz para induo parto poucas complicaes,G0000000|C0085174|G0000000|G0000000|G0000000|C0030563|G0000000|G0000000|G0000000|G0000000
96,"2 |||  ||| 0.2 ||| METHODS: Between 2008 and 2010, a total of 285 term pregnant women whom were candidate for vaginal delivery were assessed for eligibility to enter the study.",P,methods 2008 2010 total 285 term pregnant women candidate vaginal delivery assessed eligibility enter study,C0025663|G0000000|G0000000|C0439175|C1442061|C0233324|C0549206|C0043210|G0000000|C0042232|C0011209|C1516048|C0013893|C1522196|C0557651
97,25 |||  ||| 0.25 ||| Falhas s?o menos observadas e cesáreas s?o indicadas menos frequentemente com o misoprostol em rela??o à oxitocina.,N,falhas menos observadas cesreas indicadas menos frequentemente misoprostol em relao oxitocina,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0085174|G0000000|G0000000|G0000000
98,36 ||| Introduction ||| 1.10 ||| A number of trials have shown that misoprostol is more effective than oxytocin for labor induction in terms of reducing post-partum hemorrhage and time of induction.,O,trials misoprostol effective oxytocin labor induction terms reducing post-partum hemorrhage time induction,C0008976|C0085174|C1280519|C0030095|C0022864|C0205263|C0233324|C0392756|C0086839|C0019080|C0040223|C0205263
99,"96 ||| Baseline characteristics ||| 6.19 ||| As shown in Table 4, the 1 and 5-Minute Apgar scores and birth weight were similar between the two groups (p=0.05).",N,table 4 1 5-minute apgar scores birth weight p=0 05,C0039224|G0000000|G0000000|C0439232|C0741195|C0449820|C0005615|C0005910|C0369773|C0450371
100,"103 ||| Discussion ||| 7.3 ||| For example, Hofmeyr et al.",N,hofmeyr al,G0000000|C0202311
101,"7 |||  ||| 0.7 ||| The trial is registered at irct.ir, number IRCT2012061910068N1.",N,trial registered irct ir irct2012061910068n1,C0008976|C1514821|G0000000|C0022065|G0000000
102,13 |||  ||| 0.13 ||| Resumo,N,resumo,G0000000
103,"23 |||  ||| 0.23 ||| Complica??es maternas e fetais foram comparáveis entre grupos, com exce??o dos sintomas gastrointestinais, que foram encontrados mais frequentemente no grupo tratado com misoprostol (10,9 versus 3,9%, p=0,03).",N,complicaes maternas fetais foram comparveis entre grupos exceo dos sintomas gastrointestinais foram encontrados mais frequentemente grupo tratado misoprostol 10 9 versus 3 9% p=0 03,G0000000|G0000000|G0000000|C0599385|G0000000|G0000000|G0000000|G0000000|C1428722|G0000000|G0000000|C0599385|G0000000|C0026914|G0000000|G0000000|G0000000|C0085174|C0450371|G0000000|G0000000|G0000000|G0000000|C0369773|C0450371
104,"67 ||| Study population ||| 3.13 ||| In the absence of ideal uterine activites pattern after 24 hours of the first drug administration, induction was considered to have failed.",I,absence ideal uterine activites pattern 24 hours drug administration induction considered failed,C0332197|C1512612|C0042149|G0000000|C0449774|C0450371|C0439227|C0013227|C0001554|C0205263|C0750591|C0231175
105,45 ||| Introduction ||| 1.19 ||| Higher doses are linked to a greater risk for uterine tachysystole with fetal heart rate (FHR) decelerations and other complications 9,O,doses linked risk uterine tachysystole fetal heart rate fhr decelerations complications 9,C0178602|C1517892|C0035647|C0042149|C2985339|C0015965|C0018787|C0871208|G0000000|C0011100|C0009566|G0000000
106,54 ||| Introduction ||| 1.28 ||| Drug prescription method,N,drug prescription method,C0013227|C0033080|C0025663
107,"86 ||| Baseline characteristics ||| 6.9 ||| However, in comparison with the oxytocin group, patients in the misoprostol Outcome assessment Outcome in terms of mode of delivery, time from induction to delivery and induction to the beginning of the active phase, and successful inductions within 12, 18, and 24 hours were all recorded as the primary parameters used to evaluate efficacy.",O,comparison oxytocin patients misoprostol outcome assessment outcome terms mode delivery time induction delivery induction active phase successful inductions 12 18 24 hours recorded primary parameters evaluate efficacy,C1707455|C0030095|C0030705|C0085174|C1274040|C1261322|C1274040|C0233324|C1513371|C0011209|C0040223|C0205263|C0011209|C0205263|C0205177|C0205390|C0597535|C0857127|C0450371|C0450371|C0450371|C0439227|C0034869|C0205225|C0449381|C0220825|C1280519
108,105 ||| Discussion ||| 7.5 ||| One group of authors in a randomized study among 210 pregnant women compared the effectiveness of orally administered 25 μg of misoprostol every 4 hours and intravenously infused 10 units of oxytocin.,I,authors randomized study 210 pregnant women compared effectiveness orally administered 25 misoprostol 4 hours intravenously infused 10 units oxytocin,C3812881|C0034656|C0557651|C1442061|C0549206|C0043210|C1707455|C1280519|C0442027|C1521801|C0450371|C0085174|G0000000|C0439227|G0000000|G0000000|C0450371|C0439148|C0030095
109,128 ||| Discussion ||| 7.28 ||| Neonatal outcomes,N,neonatal outcomes,C1552240|C1274040
110,"126 ||| Discussion ||| 7.26 ||| However, further studies should be carried out to obtain more definite results especially with longer follow-up period.",N,studies carried definite follow-up period,C0947630|C0206243|C0439544|C0589120|C0439531
111,83 ||| Baseline characteristics ||| 6.6 ||| The mean prescribed doses of misoprostol were 7.6±3.,N,prescribed doses misoprostol 7 63,C0278329|C0178602|C0085174|G0000000|C0450371
112,89 ||| Baseline characteristics ||| 6.12 ||| There was no need for instrumental-assisted delivery in two groups.,N,instrumental-assisted delivery,C1269765|C0011209
113,"108 ||| Discussion ||| 7.8 ||| These findings were also established in two other separate studies 15,20 .",N,findings established separate studies 15 20,C2607943|C0443211|C0443299|C0947630|C0450371|C0450371
114,"43 ||| Introduction ||| 1.17 ||| Study design 6,7 .",I,study design 6 7,C0557651|C1707689|G0000000|G0000000
115,"122 ||| Discussion ||| 7.22 ||| In our trial, the mean times from induction to active phase and induction to delivery were significantly shorter in oxytocin group than in misoprostol group.",N,trial times induction active phase induction delivery shorter oxytocin misoprostol,C0008976|C0040223|C0205263|C0205177|C0205390|C0205263|C0011209|C1282927|C0030095|C0085174
116,"88 ||| Baseline characteristics ||| 6.11 ||| The secondary parameters used to evaluate efficacy or adverse events included postpartum hemorrhage, abnormal changes in maternal vital signs, and gastrointestinal symptoms (such as nausea, vomiting and diarrhea); regarding group had significantly higher rate of vaginal deliveries at time intervals of 18 and 24 hours during the study period (67.1, 79.7% versus 53.1, 61.7% respectively; all p-values were <0.05).",N,secondary parameters evaluate efficacy adverse events included postpartum hemorrhage abnormal maternal vital signs gastrointestinal symptoms nausea vomiting diarrhea rate vaginal deliveries time intervals 18 24 hours study period 67 1 79 7% versus 53 1 61 7% p-values <0 05,C0027627|C0449381|C0220825|C1280519|G0000000|C0441471|C0332257|C0086839|C0019080|C0205161|C2347083|C0442732|C0220912|C0521362|C0683368|C0027497|C0042963|C0011991|C0871208|C0042232|C0011209|C0040223|C1272706|C0450371|C0450371|C0439227|C0557651|C0439531|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|C0450371|G0000000|C1709380|G0000000|C0450371
117,"33 ||| Introduction ||| 1.7 ||| The worldwide increase in use of this procedure during recent years necessitates a careful review of indications, resulted risks, and also benefits of labor induction especially regarding two main methods including oxytocin and misoprostol (a synthetic prostaglandin E1) 5",P,worldwide increase procedure necessitates careful review indications risks benefits labor induction main methods including oxytocin misoprostol synthetic prostaglandin e1 5,G0000000|C0442805|C0184661|G0000000|C1947933|C0282443|C0392360|C0035647|C0814225|C0022864|C0205263|C0205225|C0025663|C0332257|C0030095|C0085174|C1883254|C0033554|C1704625|G0000000
118,"48 ||| Introduction ||| 1.22 ||| The aim of the present study was, therefore, to evaluate the effectiveness and the safety of orally administered 25 μg of misoprostol every 2 hours in comparison to that of intravenously infused 10 units of oxytocin for labor induction in term pregnant women.",P,aim study evaluate effectiveness safety orally administered 25 misoprostol 2 hours comparison intravenously infused 10 units oxytocin labor induction term pregnant women,C1947946|C0557651|C0220825|C1280519|C0036043|C0442027|C1521801|C0450371|C0085174|G0000000|C0439227|C1707455|G0000000|G0000000|C0450371|C0439148|C0030095|C0022864|C0205263|C0233324|C0549206|C0043210
119,"44 ||| Introduction ||| 1.18 ||| According to some clinical recommendation, based on limited or inconsistent evidence (level B), misoprostol at a dose of 50 μg every 6 hours, may be appropriate to induce labor 8 .",O,clinical recommendation based limited inconsistent evidence level misoprostol dose 50 6 hours induce labor 8,C0205210|C0034866|C1527178|C0439801|C0442809|C3887511|C0441889|C0085174|C0178602|C0450371|G0000000|C0439227|C0205263|C0022864|G0000000
120,85 ||| Baseline characteristics ||| 6.8 ||| The rate of vaginal deliveries within the first 12 hours was comparable between both groups.,I,rate vaginal deliveries 12 hours comparable,C0871208|C0042232|C0011209|C0450371|C0439227|G0000000
121,"28 ||| Introduction ||| 1.2 ||| The goal of labor induction is to stimulate uterine contractions before the spontaneous onset of labor, resulting in vaginal delivery 2 .",P,goal labor induction stimulate uterine contractions spontaneous onset labor vaginal delivery 2,C0018017|C0022864|C0205263|G0000000|C0042149|C1140999|C0205359|C0206132|C0022864|C0042232|C0011209|G0000000
122,74 ||| Statistical analysis ||| 4.1 ||| Results were given as mean plus or minus SD.,N,minus sd,C0332288|C2699239
123,"55 ||| Study population ||| 3.1 ||| Between 2008 and 2010, a total of 285 term pregnant women whom were candidate for vaginal delivery were assessed for eligibility to enter the study.",P,2008 2010 total 285 term pregnant women candidate vaginal delivery assessed eligibility enter study,G0000000|G0000000|C0439175|C1442061|C0233324|C0549206|C0043210|G0000000|C0042232|C0011209|C1516048|C0013893|C1522196|C0557651
